15220 Federal Register / Vol. 80, No. 55 / Monday, March 23, 2015 / Notices 

Form name Type of 

respondent 

Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total 

annual 

burden 

hour 

Risk Factor Assessment .......................................................... Adult Donors 100 1 19/60 40 

Dated: March 11, 2015. 

Lynn Susulske, 

NHLBI Project Clearance Liaison, National 

Institutes of Health. 

[FR Doc. 2015–06565 Filed 3–20–15; 8:45 am] 

BILLING CODE 4141–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Healthcare Research and 

Quality 

Patient Safety Organizations: Expired 

Listing From Premerus PSO, LLC 

AGENCY: Agency for Healthcare Research 

and Quality (AHRQ), Department of 

Health and Human Services (HHS). 

ACTION: Notice of delisting. 

SUMMARY: The Patient Safety and 

Quality Improvement Act of 2005, 42 

U.S.C. 299b–21 to b–26, (Patient Safety 

Act) and the related Patient Safety and 

Quality Improvement Final Rule, 42 

CFR part 3 (Patient Safety Rule), 

published in the Federal Register on 

November 21, 2008, (73 FR 70732– 

70814), provide for the formation of 

Patient Safety Organizations (PSOs), 

which collect, aggregate, and analyze 

confidential information regarding the 

quality and safety of healthcare 

delivery. The Patient Safety Rule 

authorizes AHRQ, on behalf of the 

Secretary of HHS, to list as a PSO an 

entity that attests that it meets the 

statutory and regulatory requirements 

for listing. A PSO can be ‘‘delisted’’ by 

the Secretary if it is found to no longer 

meet the requirements of the Patient 

Safety Act and Patient Safety Rule, 

when a PSO chooses to voluntarily 

relinquish its status as a PSO for any 

reason, or when a PSO’s listing expires. 

The listing from the Premerus PSO, LLC 

has expired and AHRQ has delisted the 

PSO accordingly. 

DATES: The directories for both listed 

and delisted PSOs are ongoing and 

reviewed weekly by AHRQ. The 

delisting was effective at 12:00 Midnight 

ET (2400) on January 10, 2015. 

ADDRESSES: Both directories can be 

accessed electronically at the following 

HHS Web site: http://

www.pso.AHRQ.gov/index.html. 

FOR FURTHER INFORMATION CONTACT: 

Eileen Hogan, Center for Quality 

Improvement and Patient Safety, AHRQ, 

540 Gaither Road, Rockville, MD 20850; 

Telephone (toll free): (866) 403–3697; 

Telephone (local): (301) 427–1111; TTY 

(toll free): (866) 438–7231; TTY (local): 

(301) 427–1130; Email: PSO@

AHRQ.hhs.gov. 

SUPPLEMENTARY INFORMATION: 

Background 

The Patient Safety Act authorizes the 

listing of PSOs, which are entities or 

component organizations whose 

mission and primary activity are to 

conduct activities to improve patient 

safety and the quality of health care 

delivery. 

HHS issued the Patient Safety Rule to 

implement the Patient Safety Act. 

AHRQ administers the provisions of the 

Patient Safety Act and Patient Safety 

Rule relating to the listing and operation 

of PSOs. The Patient Safety Rule 

authorizes AHRQ to list as a PSO an 

entity that attests that it meets the 

statutory and regulatory requirements 

for listing. A PSO can be ‘‘delisted’’ if 

it is found to no longer meet the 

requirements of the Patient Safety Act 

and Patient Safety Rule, when a PSO 

chooses to voluntarily relinquish its 

status as a PSO for any reason, or when 

the PSO’s listing expires. Section 

3.108(d) of the Patient Safety Rule 

requires AHRQ to provide public notice 

when it removes an organization from 

the list of federally approved PSOs. 

Premerus PSO, LLC, PSO number 

P0120, a component entity of Premerus, 

Inc., chose to let its listing expire by not 

seeking continued listing. Accordingly, 

Premerus PSO, LLC was delisted 

effective at 12:00 Midnight ET (2400) on 

January 10, 2015. 

More information on PSOs can be 

obtained through AHRQ’s PSO Web site 

at http://www.pso.AHRQ.gov/

index.html. 

Dated: March 17, 2015. 

Sharon B. Arnold, 

Deputy Director, AHRQ. 

[FR Doc. 2015–06454 Filed 3–20–15; 8:45 am] 

BILLING CODE 4160–90–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of an Exclusive 

Commercial License Agreement: 

Development of 5T4 Antibody-Drug 

Conjugates for the Treatment of 

Human Cancers 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: This is notice, in accordance 

with 35 U.S.C. 209 and 37 CFR part 404, 

that the National Institutes of Health, 

Department of Health and Human 

Services, is contemplating the grant of 

an start-up exclusive commercial 

license to practice the inventions 

embodied in U.S. Patent Application 

No. 62/034,995 entitled ‘‘Human 

Monoclonal Antibodies Specific for 5T4 

and Methods of Their Use’’ filed August 

8, 20014 [HHS Ref. E–158–2014/0–US– 

01] and all related continuing and 

foreign patents/patent applications for 

the technology family to Concortis, Inc. 

The patent rights in these inventions 

have been assigned to the Government 

of the United States of America. The 

prospective start-up exclusive 

commercial license territory may be 

worldwide and the field of use may be 

limited to the development of 5T4 

antibody drug conjugate therapeutics for 

the treatment of human cancers using 

Concortis’ proprietary conjugation 

technologies. 

DATES: Only written comments and/or 

applications for a license which are 

received by the NIH Office of 

Technology Transfer on or before April 

7, 2015 will be considered. 

ADDRESSES: Requests for copies of the 

patent applications, inquiries, 

comments, and other materials relating 

to the contemplated exclusive 

evaluation option license should be 

directed to: Whitney Hastings, Ph.D., 

Senior Licensing and Patenting 

Manager, Office of Technology Transfer, 

National Institutes of Health, 6011 

Executive Boulevard, Suite 325, 

Rockville, MD 20852–3804; Telephone: 

(301) 451–7337; Facsimile: (301) 402– 

0220; Email: hastingw@mail.nih.gov. 

SUPPLEMENTARY INFORMATION: 5T4 is an 

antigen expressed in a number of 

mstockstill on DSK4VPTVN1PROD with NOTICES